Posts Tagged ‘Dry Eye’
Oculeve Open Ups, Just A Little, On OD-01
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 047″] In this week’s OIS Podcast, we talk with Oculeve CEO Michael Ackermann about the start-up company that caught the eye of Dry Eye Leader Allergan. The dry eye space has taken a few hits lately with disappointing clinical news on the biopharmaceutical front. But the news that Allergan would pay…
Read MoreForSight VISION5
Dedicated to solving compliance problems with ophthalmic medications, ForSight VISION5 has developed Helios, a non-invasive, sustained-release drug delivery system that remains in place for 6 months. Final data from a phase 2 study is expected by the end of the year, with plans in place for a phase 3 study in Q1 2016, and a…
Read MoreJade Therapeutics
Jade’s proprietary, cross-linked, bioerodable hydrogel technology can be used alone as an ocular lubricant, or as a sustained-release vehicle for either anterior or posterior segments. The thiolated carboxymethyl HA (CMHA-S) is “an improved version of the hyaluronic acid (HA) products on the market today for dry eye,” Klausner said. The technology can be produced as…
Read MoreLacriScience
The company’s LacriPen is a handheld, portable, diagnostic tool that measures osmolarity to within 2 mOsml. It uses a technique called surface plasma residence, which calculates minute changes in the refractive index on a very thin gold film. The reflectivity minimum line produces moves as a measure of osmolarity; when in use the device is…
Read MoreLifitegrast Heads Up Promising Dry Eye Pipeline
For more than a decade, there has only been one approved pharmacologic treatment for dry eye—Allergan’s Restasis (topical cyclosporine 0.05%). This in a market estimated to be worth more than $2.4 billion, one that affects up to 100 million people worldwide, and one that is expected to grow by almost 3% yearly. Dry eye products…
Read MoreEleven’s Celniker Talks Leadership, Public Markets & Phase III Dry Eye Trials
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 021″] Eleven Biotherapeutics capitalized on exciting technology and promising clinical results for its lead dry eye product to stage a successful IPO in 2014. Abbie C. Celniker, PhD, President and CEO, talks frankly about her leadership style, dealing with public investors and how she’s managing high expectations for lead product EBI-005.…
Read MoreTearScience CEO & Co-Founder Willis Explains Dry Eye Disease’s Emergence
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 019″] TearScience CEO & Co-Founder Tim Willis discusses the emergence of dry eye disease and details how his company’s diagnostic and treatment for a source of the condition could help meet the increasing interest from physicians and patients. Podcast Guest Tim Willis Mr. Willis has more than 35 years of medical…
Read MoreForSight VISION5
ForSight VISION5 Inc. CEO John Maroney discussed his company’s novel, non-invasive insert system, Helios. Placed on the surface of the eye, under the eyelid, Helios enables glaucoma and ocular hypertensive patients to continually receive medication (such as “the drug of choice” prostaglandin A), eliminating their need to regularly administer eye drops. Results from a Phase…
Read MoreTearScience
TearScience Inc. CEO and Co-Founder Tim Willis emphasized that his company was founded for a single reason: to be the evaporative dry eye expert, and to develop a system to identify, diagnose, and treat Meibomian Gland Dysfunction, the root cause behind 90% of dry eye cases. He introduced for the first time TearScience’s LipiView II.…
Read MoreMC2 Biotek Group Offers Insights on PAD
MC2 Biotek Group’s Co-Founder and President Jesper J. Lange updated attendees on the company’s PAD technology, which may make existing drugs easier to use. The company’s lead product PADciclo is beginning Phase II testing against dry eye. MC2 Biotek has a collaboration with Moorfield Pharmaceuticals (part of Moorfield Eye Hospital) to develop a cyclosporine formulation…
Read MoreNovaliq GmbH Using Semifluorinated Alkanes To Improve Solubility Of Topical Agents
Novaliq GmbH is using semifluorinated alkanes to improve solubility of topical agents like cyclosporin and latanoprost on the ocular surface, according to CEO Bernhard Günther. CyclASol and TacroSol compounds, which are ready for Phase II studies, pair with cyclosporine for dry eye and tacrolimus for uveitis, respectively, said Günther. Novaliq also has in development other…
Read MoreIndustry Perspectives on Ophthalmic Opportunities
Gain insight on how industry thinks about a dry eye opportunity, or a cross-linking opportunity, or a uveitis opportunity. The discussion is about no so much what they liked and didn’t like about the earlier presentations at OIS@ASCRS, but in general, what does a company have to do to get their attention, take a deeper…
Read More